6 citations
,
August 2007 in “Journal of Surgical Research” Mice genetically modified to produce more Del1 protein had faster hair regrowth.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
79 citations
,
October 2003 in “PubMed” Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
April 2026 in “Frontiers in Medicine” Farudodstat may help prevent hair loss in alopecia areata by stopping immune attacks on hair follicles.
47 citations
,
February 2014 in “Journal of Cutaneous Pathology” Matrical tumors share a common growth mechanism involving the Wnt pathway and consistent PHLDA1 expression.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
February 2026 in “Applied immunohistochemistry & molecular morphology” CD34+ cells decrease in bald areas, while Sox9 stays high, suggesting hair loss in AGA is linked to stem cell issues.
IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.
1 citations
,
June 2017 in “Nature Reviews Immunology” Immune cells called Treg cells are essential for hair growth and regeneration.
20 citations
,
June 2019 in “Experimental Dermatology” The research suggests that autophagy-related genes might play a role in causing alopecia areata.
14 citations
,
January 2024 in “Skin Research and Technology” The study suggested certain immune cells might cause alopecia areata, but it was retracted.
OCT4B1 and SOX-2 levels are higher in Crohn's and ulcerative colitis patients, possibly aiding tissue repair.
February 2014 in “Plastic and Reconstructive Surgery” The document doesn't provide a clear conclusion or detailed findings about the impact of certain cells on cancer treatment.
May 2024 in “The Journal of Immunology” IL-27 can prevent hair loss in alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
10 citations
,
April 2013 in “Veterinary dermatology” A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
2 citations
,
April 2025 in “Cureus” Ki-67 levels do not predict treatment response in triple-negative breast cancer.
May 2018 in “The journal of immunology/The Journal of immunology” Mutations in the FOXN1 gene cause severe immune issues but don't affect hair and nails.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
15 citations
,
July 2016 in “Biochemical Journal” Wnt proteins from certain skin cells are crucial for normal hair growth and renewal.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
August 2016 in “Journal of Investigative Dermatology” The enzyme CD73 helps control human hair growth and could be targeted to treat hair growth disorders.
1 citations
,
April 2017 in “Journal of Dermatological Science” Certain immune cells may cause hair loss by reacting to stressed hair follicles.
Activating certain hair follicle cells could prevent hair loss from cancer treatments.
Keratinocytes can reverse the effects of the GNAQ oncogene, inhibiting melanoma cell growth.
3 citations
,
January 2016 in “Journal of Clinical & Cellular Immunology” Targeting CXCL10 may help treat alopecia areata.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
October 2025 in “Transactions on Materials Biotechnology and Life Sciences” Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.